share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4：持股變動聲明-高管 Shutterly Andrew
美股sec公告 ·  08/02 05:51
牛牛AI助理已提取核心訊息
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
致富金融(臨時代碼)的代理首席財務官Andrew Shutterly於2024年7月31日購買了1,259股普通股。交易價格爲每股5.41美元，總投資約爲6,811.99美元。此次收購後，Shutterly在公司的直接持股增至11,372股普通股。該交易反映出直接擁有利益，根據交易代碼“A”，報告爲授予、獎勵或其他收購等。
致富金融(臨時代碼)的代理首席財務官Andrew Shutterly於2024年7月31日購買了1,259股普通股。交易價格爲每股5.41美元，總投資約爲6,811.99美元。此次收購後，Shutterly在公司的直接持股增至11,372股普通股。該交易反映出直接擁有利益，根據交易代碼“A”，報告爲授予、獎勵或其他收購等。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。